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LETTERS TO THE EDITOR
The IASLC Lung
Cancer Staging Project:
Revision Proposal of
Pleural Effusion and
Controlateral Nodule
Staging
To the Editor:
The International oncology commu-
nity is urged to fully appreciate the major
effort of the International Association for
the Study of Lung Cancer (IASLC) in the
aim of revising lung cancer tumor, node,
metastasis (TNM) staging criteria. It is the
first time that a validation process of TNM
categories has been performed on an ex-
tremely wide database and case accrural
from all over the world.1
Here, we would like to provide
some suggestions in the proposal set-
ting, due to the major challenge of de-
fining the pleural effusion (PE)-related
disease, which, under the anatomic pro-
file is a locoregional disease. The inclu-
sion of PE by the IASLC committee in
the M1 category has been based on the
adverse prognostic weight more than an-
atomic spread. In our opinion, T4 cate-
gory might include PE distinguishing it
topographically from metastatic disease.
We would therefore suggest to define
the pleural involvement as a new T4b
category which, based on poor survival,
should be included in the stage IV to-
gether with M1. This classification
would allow to distinguish T4b from
T4a which is included in the IIIB group.
In this way, the stage IV, grouping PE
(T4b), controlateral nodule (M1a) and
other metastatic lesions at different sites
(M1b), would, in any case, include all
clinical conditions requiring a similar
therapeutic approach where the main-
stay would be systemic chemotherapy.
Our proposal take in account the emerg-
ing opportunities in staging nodules dis-
tinct from the primary tumor, including
T3 for the nodule in the same lobe of the
primary (T4 according to TNM 6) and
T4 for a nodule in a different ipsilateral
lobe (M1 according to TNM 6).2 In the
IASLC-International Staging Commit-
tee proposal, the new M1a category
would include two different conditions,
even with a similar prognostic impact:
PE or controlateral nodule.
In the “prospective data capture”
starting in 2008,1 by a large amount of
data collection, it might be useful to
differentiate clinicopathological settings
to define the role of controlateral lesions
in the most appropriate way. Within sur-
vival curves reported by Postmus et al.,3
PE and controlateral nodules appeared
close but distinguishable. It would be
interesting to maintain the chance of
recognizing a controlateral nodule as a
new primary even when histology does
not allow a clear definition, taking in
account that a new primary might allow
a curative resection with a clearly better
clinical outcome when compared with a
resectable metastatic nodule.
It is reasonable to predict that
emerging molecular profiling technolo-
gies4 will allow in the next future a clear
identification of a metastatic nodule
from a second primary, providing the
opportunity to further define the “best
stage,” which even at present provides a
more favorable estimate when compared
with “clinical stage” for PE.3 On these
bases, it is possible to predict that the
identification of true metastatic nodules
will further allow a better prognostic
discrimination of M1 (true metastatic
disease) when compared with the pro-
posed T4b PE (locoregional disease).
This concept can be understood in the
light of “Will-Rogers phenomenon” or
stage migration, which happens when
novel diagnostic or staging approaches
and technologies are translated in the
clinical practice. These changes will al-
low a better definition of close but rec-
ognizable prognostic conditions.5
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Reply to the Letter to
the Editor Entitled The
IASLC Lung Cancer
Staging Project: Revision
Proposal of Pleural
Effusion and
Contralateral Nodule
Staging, by V. Barbieri,
P. Tassone, and P.
Tagliaferri
In Reply:
We read with interest the letter
by Dr. Barbieri et al. regarding the
recommendations for changes in the
forthcoming edition of the tumor, node,
metastasis (TNM) classification for lung
cancer proposed by the International Stag-
ing Committee (ISC) of the International
Association for the Study of Lung Can-
cer.1 They raise two important issues: the
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suitability of the recommendation to re-
classify malignant pleural effusion as
M1a, and, therefore, stage IV; and the
concern of classifying contralateral nod-
ules as M1a, disregarding the possibility
that some of these nodules may be second
primary tumors.
The criteria of the ISC to propose
changes to the present TNM classifica-
tion was based on survival differences
and clinical judgment. The issues Dr.
Barbieri et al. refer to in their letter were
intensively discussed. For most propos-
als, more than one possibility was avail-
able, i.e., to retain the descriptor in the
existing category, but identified by al-
phabetical subscripts, as Dr. Barbieri et
al. propose, or to allow descriptors to
move to a category containing other de-
scriptors with a similar prognosis. Regard-
ing malignant pleural effusion, it was
thought that, in most cases, it was the
consequence of metastatic spread in the
pleura. Malignant pleural effusion, al-
though confined to the chest, is treated as
disseminated disease. These two facts fa-
vored the proposal to reclassify it as M1
disease, instead of maintaining it in the T4
category. However, the proposal of Dr.
Barbieri et al. to reclassify it as T4b and
transfer this category to stage IV is also
valid was considered by the ISC, but was
not chosen to avoid the complexity of the
resulting TNM subsets.
The problem with additional nod-
ules in the same lobe, in another ipsilat-
eral lobe, and in the contralateral lung is
unsolved and will require a large num-
ber of well-registered cases. All of these
nodules, now proposed to be classified
as T3, T4, and M1a, respectively, can be
second primaries, metastasis, or non-
neoplastic disease. There rarely is pre-
operative pathologic diagnosis of these
additional nodules and, even postopera-
tively, unless they have different cell
types, second primaries and metastasis
are practically impossible to differenti-
ate with routine pathologic techniques.
The ISC is well aware of this fact and
for the prospective collection of data,
which will be used to inform the eighth
edition of the TNM classification, a de-
tailed dataset has been designed, includ-
ing molecular studies where they are
available. We hope that the prospective
project of the ISC will bring some light
to this difficult problem. In the mean-
time, we must keep in mind that the
TNM classification suggests but does
not dictate a certain type of treatment for
each TNM category. Therefore, the fact
that contralateral nodules are classified as
M1a disease does not preclude surgical
treatment if both the primary tumor and
the contralateral nodule are deemed com-
pletely resectable, and the patient is ade-
quately fit for the planned operation. We
know now that if the contralateral nodule
is a second primary, it will have a better
prognosis than a metastatic nodule; and if
it is a metastasis, its prognosis will be
better than that of metastasis outside the
chest.
We thank Dr. Barbieri et al. for
their thoughtful comments and for their
interest in lung cancer staging.
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IASLC Lung Cancer
Staging Project—A
Radiologist Perspective
To the Editor:
We read recent articles from the
International Association for the Study
of Lung Cancer staging project (espe-
cially relating to T and N staging) with
interest.1,2 We commend the tremendous
work of the team and mostly support the
proposed new staging system. There are
at least three areas where we, as radiol-
ogists, feel that this system is subopti-
mal and find it difficult to stage patients
in day-to-day practice.
First, relating to T descriptor,
Lymphangitis carcinomatosis (LC), al-
though uncommon, is a distressing form
of metastatic lung cancer and has major
impact in quality of life with an unfavor-
able prognosis.3 LC can occur from lym-
phatic invasion from the primary tumor or
nodal spread.4 In other tumors, particu-
larly, spread is thought to be hematoge-
nous. Computed tomography (CT) is the
imaging modality of choice and in most
cases radiologists are the first to recognize
it. In the tumor, node, metastasis (TNM)
staging, there is no specific reference to
LC, and we have always felt it difficult to
give an accurate stage when present. In
our practice, most patients with LC have
advanced disease and are not candidates
for radical treatment. LC may be seen in
the same lobe as the primary lesion or may
involve other ipsilateral lobes or both
lungs. This is analogous to a satellite nod-
ule but is likely to carry a poorer progno-
sis. The histologic diagnosis of lym-
phangitis is often not confirmed.
With regards to the N stage, we
agree with your findings of prognostic
difference between single N1/N2 nodes
versus multiple N1/N2 nodes. There is
substantial heterogeneity in clinical pre-
sentation, treatment, and prognosis re-
lating to N2 disease.5 This has been
recognized previously and subgroups of
N2 disease have been proposed. At one
end of this spectrum there is occult N2
disease, not found on conventional imag-
ing workup with CT and CT/positron
emission tomography (PET), but found at
surgery after lymph node dissection. At
the other end is N2 disease invading sur-
rounding mediastinal structures, analo-
gous to T4 stage. The revised TNM in
such cases does not reflect the true picture
of the disease. Nodal disease invading
mediastinal structures is analogous to T4
for the primary tumor stage. It may often
be difficult on CT where there is contigu-
ous disease to differentiate where the pri-
mary lesion stops and nodal disease starts.
Historically, CT has been the
primary investigation with its well-
recognized limitations. The introduc-
tion of PET and then CT/PET gives
more accurate information and is in-
creasingly used in routine staging if
patient is fit for radical therapy. The T
stage may be expected to take account
of metabolic activity in the tumor
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